These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 16304153

  • 1. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA.
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [Abstract] [Full Text] [Related]

  • 5. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R, Bergen PJ, Rogers KE, Kirkpatrick CMJ, Wallis SC, Huang Y, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB.
    Antimicrob Agents Chemother; 2019 Dec 20; 64(1):. PubMed ID: 31636062
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Feb 20; 57(2):153-61. PubMed ID: 16930925
    [Abstract] [Full Text] [Related]

  • 11. Modelling time-kill studies to discern the pharmacodynamics of meropenem.
    Tam VH, Schilling AN, Nikolaou M.
    J Antimicrob Chemother; 2005 May 20; 55(5):699-706. PubMed ID: 15772138
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains.
    Drenjancević D, Vranes J, Bedenić B, Sakić-Zdravcević K.
    Coll Antropol; 2007 Mar 20; 31(1):221-5. PubMed ID: 17598405
    [Abstract] [Full Text] [Related]

  • 15. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.
    Antimicrob Agents Chemother; 2017 May 20; 61(5):. PubMed ID: 28264846
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
    Lee DG, Choi SM, Shin WS, Lah HO, Yim DS.
    Int J Antimicrob Agents; 2006 Oct 20; 28(4):333-9. PubMed ID: 16942864
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.
    Li X, Wang L, Zhang XJ, Yang Y, Gong WT, Xu B, Zhu YQ, Liu W.
    Antimicrob Agents Chemother; 2014 Nov 20; 58(11):6773-81. PubMed ID: 25182633
    [Abstract] [Full Text] [Related]

  • 20. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA, Banevicius MA, Fan HW, Nicolau DP.
    Antimicrob Agents Chemother; 2007 Apr 20; 51(4):1481-6. PubMed ID: 17283197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.